Founded by a team of world-class scientists returning to China who have been selected for the Chinese “National Thousand Talents Program”, Clover Biopharmaceuticals is passionate about developing transformative biologic therapies for the millions of Chinese patients who currently do not have access to modern biological medicines. Seeking to Change the Paradigm in China | Emerging only recently from the advent of modern biotechnology, biologics today represent the majority of the world’s most efficacious therapies due to their high target specificity and lower off-target toxicities compared to small molecule drugs. In fact, biologics generated over US$150 billion in global sales and represented over 70% of the combined sales from the top 10 drugs worldwide in 2015. However, few of these therapies are approved in China, and most Chinese people are not able to access them at affordable prices. Clover is seeking to change this paradigm. Decades of Biologics Development & Manufacturing Expertise | These biological drugs are highly-complex and require extensive technical expertise to develop and manufacture that most domestic Chinese companies do not have. Our leadership team has decades of experience in biologics development needed to successfully bring such therapies to market.  Developing Novel Biologics & Differentiated Biosimilars | We are developing a robust portfolio of novel biologics and differentiated biosimilars to treat the world’s most debilitating diseases – autoimmune, cancer and infectious diseases. We are utilizing our proprietary Trimer-Tag© technology to develop novel, trimerized fusion-protein therapies. Our primary focus is on the China market but plan to develop our therapies globally if they meet an unmet need for patients worldwide. 三叶草生物制药是由一组世界海外归来的科学家创立，其核心团队包括5位国家“千人计划”入选者。我们热衷于为数以百万计无法获得现代生物药品的中国病患者研发革新性的生物靶向制药。三叶草生物团队获得了2009年国务院侨办颁发的 “华侨华人创业团队”称号，并入选2012年成都市首批团队。公司创新性靶向生物制药研发共获得3项国家十二五“重大新药创制”重大专项及“抗体药物关键技术”863计划的立项支持和认可， 并受到各级地方政府， 包括成都高新区、 成都市和四川省的扶持。寻求改变中国生物制药现状 | 随着现代生物技术的问世，生物制药虽在近期才逐渐兴起却已因其相比小分子药物更高的专一性和较低的副作用成为了当今世界大多数有效的疾病治疗手段。事实上, 生物制药在全球已拥有超过1500亿美金的销售额并占据了2015年世界销售额排名前10名药物的70%。但是，只有极少一部分生物制药疗法在中国获得到了批准；算是被批准的药物，它们的对于绝大多数中国人来说也是望尘莫及，。三叶草生物致力于改变这个现状。数十年的生物制药研发与生产经验 | 生物制药是一个极其复杂的系统工程、而且需要大量目前中国国内企业所不具备的专业技术来研发和制造。我们的核心领导团队具有数十年的生物制药研发及产业化经验，将现代生物制药成功地推向市场。创新性生物靶向药物和革新性生物仿制药 | 我们致力于用三叶草的“蛋白质三聚体化”（Trimer-Tag© ）生物逻辑制药平台技术为支撑，以我们独有的AP-TAG 技术为药物高通量筛选技术手段，从事多种创新性的三聚融合蛋白靶向药物、疫苗和革新性生物仿制药的研发，用其治疗世界上各种严重的疾病 – 包括自身免疫性疾病，癌症和传染性疾病。​中国市场是我们目前的首要焦点；但如果世界上其他地区有未满足的对生物制药的需求，我们将在全球范围内研发和推广我们的革新性生物制药及疗法。